A5002988007- Systemic Lupus Erythematosus Research
- Platelet Disorders and Treatments
- Venous Thromboembolism Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Renal Diseases and Glomerulopathies
- Blood Coagulation and Thrombosis Mechanisms
- Systemic Sclerosis and Related Diseases
- Atrial Fibrillation Management and Outcomes
- Complement system in diseases
- Vasculitis and related conditions
- Aortic aneurysm repair treatments
- Abdominal vascular conditions and treatments
- COVID-19 Clinical Research Studies
- Connective tissue disorders research
- Hepatitis C virus research
- Infectious Aortic and Vascular Conditions
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- Vascular Malformations and Hemangiomas
- COVID-19 and healthcare impacts
- Intramuscular injections and effects
- Innovations in Educational Methods
- Rheumatoid Arthritis Research and Therapies
- Peripheral Neuropathies and Disorders
- Central Venous Catheters and Hemodialysis
Université de Lorraine
2018-2024
Inserm
2018-2024
Défaillance Cardiovasculaire Aiguë et Chronique
2019-2023
Centre Hospitalier Régional et Universitaire de Nancy
2017-2022
To assess the safety and efficacy of TNF-α antagonists tocilizumab in patients with Takayasu arteritis (TAK). A total 209 TAK [median age 29 years (interquartile range 7-62)], 186 (89%) females] were included. They received either [n = 132 (63%) 172 lines; infliximab (n 109), adalimumab 45), golimumab 8), certolizumab 6) etanercept 5)] or 77 (37%) 121 i.v. s.c. 95 26 cases, respectively]. complete response at 6 months was evidenced 101/152 (66%) on 75/107 (70%) tocilizumab. Age ≥30 [odds...
Antibodies binding to domain I of β2-glycoprotein (aDI) and activated protein C (APC) resistance are associated with an increased risk thrombosis in cross-sectional studies. The objective this study was assess their predictive value for future thromboembolic events patients antiphospholipid antibodies (aPL) or syndrome.This prospective multicenter cohort included consecutive aPL systemic lupus erythematosus. We followed 137 (43.5 ± 15.4 year old; 107 women) a mean duration 43.1 20.7...
Catastrophic antiphospholipid syndrome (CAPS) is a severe, rare complication of (APS), but cutaneous involvement has not yet been adequately described.To describe during CAPS, its clinical and pathological features, outcomes.This cohort study was retrospective analysis patients included in the French multicenter APS/systemic lupus erythematosus register (ClinicalTrials.gov: NCT02782039) by December 2020. All meeting revised international classification criteria for CAPS were included, with...
In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.We conducted a retrospective study referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia Russia regarding biological-targeted therapies TAK, since January 2017 to September 2019.A total TAK patients received at least 3 months therapy were included study. Among them, 91 18 SC tocilizumab, respectively. A...
APS is a heterogeneous disease with different phenotypes. Using an unsupervised hierarchical cluster analysis, we aimed to determine distinct homogeneous phenotypes among patients.We performed observational, retrospective study of patients enrolled in the French multicentre 'APS and SLE' registry who met Sydney classification criteria. The clustering process involved multiple correspondence analysis followed by ascendant analysis; it used 27 variables selected cover broad range clinical...
Antiphospholipid syndrome (APS) is characterized by several clinical manifestations such as venous and arterial thrombosis associated with persistent antiphospholipid antibodies (aPL). Several studies confirmed that retinal vein occlusion was the most common APS ocular manifestation. The purpose of this study to identify ophthalmologic in a homogeneous cohort well-defined persistently aPL-positive patients determine variables these manifestations.APL-positive were selected from two research...